AG221|AG 221|mutated IDH2 inhibitor|DC Chemicals

AG221|AG 221|mutated IDH2 inhibitor|DC Chemicals

AG-221 is an orally available, selective, potent inhibitor of the mutated IDH2 protein.

Product Name: AG-221 |Catalog Number:  DC8374 | cas: 1446502-11-9 | Other names: AG221,AG 221 | Chemical name： | Molecule Formula: C19H17F6N7O | MW: 473.14

AG-221 is an orally available, selective, potent inhibitor of the mutated IDH2 protein, making it a highly targeted investigational medicine for the potential treatment of patients with cancers that harbor an IDH2 mutation. AG-221 has received orphan drug and fast track designations from the U.S. FDA. In September 2013, Agios initiated a Phase 1 multicenter, open-label, dose escalation clinical trial of AG-221 designed to assess the safety and tolerability of AG-221 in advanced hematologic malignancies. In October 2014, Agios initiated four expansion cohorts as part of the ongoing Phase 1 study and expanded its development program with the initiation of a Phase 1/2 study of AG-221 in advanced solid tumors.

For research and scientific purpose only, not for human use.